CEO Bob Proulx Featured on Biotech2050 Podcast
Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed…
Vesting of Performance Rights and Appendix 2A
Imagion Biosystems has today advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO, Bob…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems announce that it has received a total of $82,939.98 for the exercise of Listed Options. Comprised of $64,189.98 for 2,139,666 Listed…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems gives notice that, on 27 August 2020 the Company issued 6,080,000 fully paid ordinary shares (Shares) in the Company as the result of…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems announce that it has received $122k for the exercise of 4,080,000 listed options exercisable at 3 cents expiring on 28 April 2023. In…
Appendix 3G
The attached ASX announcement in relation to IBX Appendix 3G was released to market. Read the announcement.
Appendix 4D and Half Year Results H1 2020
Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…